234
Participants
Start Date
June 20, 2018
Primary Completion Date
March 14, 2019
Study Completion Date
March 27, 2019
RVL-1201
RVL-1201 ophthalmic solution, 0.1%
Vehicle ophthalmic solution
Vehicle placebo ophthalmic solution
South Shore Eye Care, Wantagh
Rochester Ophthalmological Group, Rochester
Seidenberg Protzko Eye Associates, Havre de Grace
Cornerstone Eye Care, High Point
CEENTA, Charlotte
Coastal Research Associates, Roswell
Maitland Vision Center, Maitland
Sabal Eye Care, Longwood
Shettle Eye Research, Largo
Sarasota Retina Institute, Sarasota
West Coast Eye Institute, Lecanto
Hernando Eye Institute, Brooksville
East Florida Eye Institute, Stuart
Nashville Vision Associates, Nashville
Mississippi Eye Associates, Ocean Springs
Abrams Eye Center, Cleveland
Apex Eye, Cincinnati
Apex Eye, Cincinnati
Drs. Quinn, Foster & Associates, Athens
Comprehensive Eye Care, Washington
Silverstein Eye Centers, Kansas City
Heart of America Eye Care, Shawnee Mission
Kennar Eye Care, Pittsburg
R & R Research, San Antonio
Round Rock Eye Consultants, Austin
Texan Eye / Keystone Research, Ltd., Austin
Barnet, Dulany Perkins, Phoenix
North Valley Eye Medical, Mission Hills
Pendelton Eye Center, Oceanside
Eye Research Foundation, Newport Beach
Michael K. Tran, MD Inc., Westminster
Orange County Ophthalmology Medical Group, Garden Grove
North Bay Eye Associates, Petaluma
Danbury Eye Physicians and Surgeons, Danbury
Lake Travis Eye and Laser Center, Lakeway
RVL Pharmaceuticals, Inc.
INDUSTRY